Video

Questions raised by kidney cancer epidemiology update

Author(s):

Urology Times staff

“The biggest question that arose from this is, ‘Why is there such a lack of large familial genetic disorder epidemiological studies?’ says Laura Bukavina, MD, MPH.

In this video, Laura Bukavina, MD, MPH, and Sarah P. Psutka, MD, MS, discuss the questions raised by the European Urology study, “Epidemiology of Renal Cell Carcinoma: 2022 Update.” Bukavina is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Psutka is an associate professor of urology at University of Washington Medical Center, Seattle.

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Ravi Munver, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman having telemedicine appointment with doctor | Image Credit: © Jacob Lund - stock.adobe.com
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Related Content
Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC
September 25th 2024

Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC

Hannah Clarke
"The encouraging results suggest that alternating pazopanib with bevacizumab is a promising treatment regimen for renal cell carcinoma patients in the favorable risk group," says Saby George, MD, FACP.
Benmelstobart plus anlotinib improves PFS, ORR vs sunitinib in aRCC
September 19th 2024

Benmelstobart plus anlotinib improves PFS, ORR vs sunitinib in aRCC

Hannah Clarke
According to the authors, "These results support the use of Benmelstobart plus anlotinib as a new first-line treatment for advanced RCC.”
Serum glycoproteins may predict response to nivolumab/cabozantinib in aRCC
September 16th 2024

Serum glycoproteins may predict response to nivolumab/cabozantinib in aRCC

Hannah Clarke
On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01).
Ipilimumab / nivolumab significantly improves 12-month nccRCC survival in SUNNIFORECAST
September 14th 2024

Ipilimumab / nivolumab significantly improves 12-month nccRCC survival in SUNNIFORECAST

Kevin Kunzmann
Late-breaking data from ESMO 2024 suggest ipilimumab / nivolumab may be a new standard of care for non-clear cell renal cell cancer.
Study reveals disparities in immunotherapy use for patients with kidney, bladder cancer
September 4th 2024

Study reveals disparities in immunotherapy use for patients with kidney, bladder cancer

Hannah Clarke
“Our study highlights critical gaps in health care equity when it comes to treatments that have been shown effective in prolonging survival,” says Solomon Woldu, MD.
Systemic therapy after adjuvant IO shows benefit in subset of renal cell carcinoma tumors
August 20th 2024

Systemic therapy after adjuvant IO shows benefit in subset of renal cell carcinoma tumors

Hannah Clarke
"Overall, we found that patients with recurrent RCC following adjuvant IO continued to have responses to different types of first-line systemic therapy," says Talal El Zarif, MD.
© 2024 MJH Life Sciences

All rights reserved.